Anti cancer activity of rodent tuber (Thyphonium flagelliforme (lodd.)Blume on human breast cancer t47d cells

Arief Nurrochmad, Endang Lukitaningsih, Edy Meiyanto


The incidence of breast cancer in developing countries showed an increase from year to year. The efforts of cancer prevention or treatment of the more important given the frequency of occurrence is quite high. Several studies have been focuses on natural products as agents of cancer chemoprevention and as co-chemotherapy agent against cancer. One of medicinal plant that is widely used as anticancer is rodent tuber (Thyphonium flagelliforme (Lodd.) Blume). In present study, we investigated the anticancer acitivty of rodent tuber extract (RTE) in vitro. Study of anti-proliferative conducted on human breast cancer primary T47D cells. Furthermore, the present study also investigated the molecular mechanisms of cell cycle arrest and induction of apoptosis. The study of rodent tuber as co-chemotherapy is determined by examining the effects on T47D and its combination with tamoxifen (TAM). The results showed the cytotoxic effects of RTE on T47D cells with IC50 value of 632 mg/mL. Low concentration RTE (below 250 ug/mL) are proliferative, while the concentration above 250 mg/mL indicated cytotoxic effect. Based on the calculation of Combination Index (CI), combination of RTE with TAM yielded a value above 10 indicated a strong antagonistic effect. In observation of apoptosis, low concentration of RTE (63 µg/mL) stimulate apoptosis better than high concentration of 250 mg/mL. However, the combination study with 5 nM TAM reduced the induction of apoptosis. Furthermore, the observation cell cycle arrest by flowcytometry, demonstrated that RTE 63 and 250 mg/mL increase the population of sub G1 phase respectively from 14.8% to 53.19 and 32.90%. These results suggest that RTE able to induce cell cycle to apoptosis, but low concentration of RTE more effective than high concentration. Similar to apoptosis observation, the combination of RTE and TAM also demonstrated the antagonistic effect by reducing the population of Sub-G1 RTE (63 mg/mL) and TAM 5 nM, respectively from 53.19% and 44.50% to 35.86%. All finding results of this study provide information that the use of rodent tuber extract (RTE) alone is better than the combination with TAM. In addition, the use of RTE together with TAM reduced the effectiveness of TAM in the treatment of breast cancer.

Keywords: Rodent tuber (Thyphonium flagelliforme (Lodd.) Blume), anti cancer, chemoprevention, T47D cells.

Full Text:



Singletary K, MacDonald C, Lovinelli M, Fisher C, Wallig M. Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene, Carcinogenesis 1998;9(6):1039–1043.

Yaar M, Eller MS, Panova I, Kubera J, Wee LH, Cowan KH, Gilchrest BA. Telomeric DNA induces apoptosis and senescence of human carcinoma cells, Breast Cancer Research 2007;9:R13.

Choo CY, Chan KL, Sam TW, Hitotsuyanagi Y, Takeya K. The cytotoxicity and chemical constituents of the hexane fraction of Thyponium flagelliformae (Araceace). J Ethnopharmacol 2001;77:129–131.

Lai CS, Mas RH, Nair NK, Majid MI, Mansor SM, Navaratnam V. Thyponium flagelliformae inhibits cancer cell growth in vitro and induced apoptosis: an evaluation by the bioactivity guided approach. J. Ethnopharmacol 2008;118:14–20.

Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991;179:661–667.

Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 1994;30A(11):1675–1682.

Hsieh CY, Santell RC, Haslam SZ, and Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833–3838.

Shao ZM, Shen ZZ, Fontana JA, Barsky SH. Genistein’s “ER-dependent and independent” actions are mediated through ER pathways in ER-positive breast carcinoma cell lines. Anticancer Res 2000;20:2409–2416.

Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31–40.

Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett 1998;130:143–152.

Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360:817–824.

Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98–101.

Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women. Lancet 1998;352:93–97.

J Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296–300.

Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids, Environ Health Perspect 1998;106:807–812.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five vs more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptorpositive tumors. J. Natl Cancer Inst 1996;88:1529–1542.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.


  • There are currently no refbacks.

Copyright (c)

                AR Journals

Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

     (Design) 2009-2021


Follow @arjournals on Twitter